The US Food and Drug Administration (FDA) is at a crossroads. There is an urgent need to strengthen the integrity of drug approvals and rejections by diffusing the decision-making authority of individual officials and improving transparency when disagreements arise.

Despite mixed efficacy outcomes, a phase 1/2 umbrella trial brings the glioblastoma field closer to a new era of diagnostic precision and targeted therapy.

The STARD-AI statement, which was developed through a multistage process involving over 240 international stakeholders, provides a minimum set of criteria that allows for comprehensive reporting of AI-centered diagnostic test accuracy studies.

Ophthalmology could be the first medical specialty fundamentally transformed by artificial intelligence. Pearse Keane recalls an early breakthrough in this journey.

In a cross-trial analysis, combined treatment with medications that have individually shown to improve cardiovascular outcomes in heart failure with mildly reduced or preserved ejection fraction demonstrates substantial benefit, including for event-free survival.

In the double-blind, placebo-controlled phase 2 ARGO trial, patients with active psoriatic arthritis treated with a nanobody targeting IL-17A and IL-17F showed substantially better disease response rates compared with those receiving placebo treatment.

A modeling approach to assess the global risk of Plasmodium falciparum histidine-rich protein 2 and 3 gene deletions identifies ten priority African countries for surveillance and could inform malaria control policies.

Large-scale longitudinal health records reveal consistent association of varicella-zoster virus reactivation with dementia.

A systematic review and meta-analysis of clinical trials investigating the efficacy and safety of obesity management medications reported tirzepatide and semaglutide to be the most effective in reducing body weight and obesity-related complications.

In a prospective study enrolling 1,222 patients from 22 emergency departments, a device using a machine-learning-based signature of blood mRNAs demonstrated clinically acceptable performance to diagnose bacterial and viral infections and to predict the all-cause need for critical care interventions within 7 days, with benchmark to established biomarkers and risk scores.

Obesity and associated complications can be managed by obesity medications, prompting the revision of criteria for the diagnosis and staging of this disease.

When clinical trials are suddenly halted by US funding cuts, there are repercussions for investigators and patients, and they do not stop at borders.

The US Food and Drug Administration (FDA) is at a crossroads. There is an urgent need to strengthen the integrity of drug approvals and rejections by diffusing the decision-making authority of individual officials and improving transparency when disagreements arise.

Patients with obesity achieved significant weight loss and cardiometabolic benefits with oral orforglipron — offering a potential alternative to injectable GLP-1 receptor agonists.

Smoke from 2023 Canadian wildfires led to increased PM_2.5 exposure across North America and Europe, leading to thousands of acute and chronic deaths.